The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Emerging Lipid-Lowering Therapies in Secondary Prevention
Mahtta, D., Virani, S. S., & Bavry, A. A. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0607-z
Salinas, P., & Salazar, C. (2018) · Revista Argentina de Cardioangiología Intervencionista · doi:10.30567/raci/201801/0198-0203
Regulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System
Kovrov, O. (2019) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Pawlik, J., & Wrześniok, D. M. (2019) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0013.3673
Gilyarevsky, S. R., Golshmid, M. V., Kuzmina, I. M., & Sinitsina, I. I. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-16-110-117
Encouragement of Super-aggressive LDL-lowering Therapies
Tada, H., Sakata, K., Takamura, M., & Kawashiri, M. (2019) · Journal of Coronary Artery Disease · doi:10.7793/jcad.25.19-00005
Michalski, B. W. (2018) · Folia Cardiologica · doi:10.5603/fc.2018.0018
Genetic disorders of lipoprotein metabolism
Bhatnagar, D., Schofield, J. D., & Soran, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809356-6.00014-9 · Cited by 1
Statins in primary prevention: is the enthusiasm justified?
Chopra, A. K., & Yadav, R. K. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.07.021
[First-line chemotherapy for unresectable and metastatic colorectal cancer].
Satoh, T. (2014) · PubMed
The Low-Density Lipoprotein Cholesterol Hypothesis: An Update
Rengarajan, R., Tecson, K. M., & McCullough, P. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_7
How ApoB Measurements Could Improve Prevention of Cardiovascular Disease
Sniderman, A. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_29
Prevention of Stroke by Lowering Blood Cholesterol Concentrations
Paciaroni, M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316286234.017
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
Masuda, D., & Yamashita, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed165
"The higher the better" seems to be no longer true for HDL-cholesterol
Rosolová, H. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.165
Apolipoprotein A-I Mimetics for Treatment of the Residual Risk of Cardiovascular Disease
Miura, S., Suematsu, Y., Imaizumi, S., Yahiro, E., Kuwano, T., Uehara, Y., & Saku, K. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e13
Chen, H., Chen, W., Li, H., Xu, H., Yuan, F., Sheng, L., Liu, C., Lin, P., Yang, M., Li, X., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01794-8
Generoso, G. (2021) · doi:10.11606/t.5.2021.tde-08092021-111523
Moors, J., Krishnan, M., Sumpter, N., Takei, R., Bixley, M., Cadzow, M. J., Major, T. J., Phipps‐Green, A. J., Topless, R., Merriman, M. E., et al. (2021) · medRxiv · doi:10.1101/2021.09.11.21263438
Innovative Lipid Biomarkers and Long-Term Outcomes
Anderson, J. L. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.192996734
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_6075
(2018) · Wiley eBooks · doi:10.1002/9781118829875.refs
Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management
Cupido, A. J., Stoekenbroek, R. M., & Kastelein, J. J. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45457-9_23
Is a high concentration of high-density lipoprotein cholesterol still relevant?
Hanselim, H. (2021) · Intisari Sains Medis · doi:10.15562/ism.v12i2.1036
Diniz, E. T., Cardoso, A. C. S., & Bandeira, F. A. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_44
Results of the REVEAL study. Why should we not welcome a new lipid-lowering agent?
Masana, L. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.11.003
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_6075-1
Farnier, M. (2021) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(21)45461-9
Klose, G., & Schwabe, U. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_32
Better Health Related Quality of Life Reduced Elevated Lp(a) Levels in ManPreprint
Bao, J., Wen, Z., Tang, Y., Sun, R., Huang, C., Wang, J., & Zhang, Y. (2020) · doi:10.21203/rs.3.rs-67835/v1
Liu, J., Yu, G., Yu, X., Liu, Y., & Wang, W. (2020) · Research Square · doi:10.21203/rs.3.rs-58456/v1
Wei, M., Liu, J., Lai, J., Leng, M., Ye, Z., & Guo, K. (2021) · Research Square · doi:10.21203/rs.3.rs-275396/v1
Davidson, M. H. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000512
Wehling, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00027-1
Fazio, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736866539.793567220
The Role of level and function of High Density Lipoprotein (HDL) in Cardiovascular Diseases
آقاسی زاده, م., غیور مبرهن, م., کاظمی, ط., آوان, ا., & میری مقدم, ا. (2020) · مجله علمی دانشگاه علوم پزشکی بیرجند · doi:10.32592/jbirjandunimedsci.2020.27.2.100
Passarelli, M., Yokoyama, S., & Sposito, A. C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.963463
Prevention is still the key to success
Agewall, S. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac046
Abordagem atual das dislipidemias
Juliani, F. C., & Rocha, V. Z. (2021) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2021.20.4.20-31
Li, Q., Wang, Y., Sun, M., Wang, R., Wang, M.-G., Zeng, J., Zhu, H., & Lv, C. (2022) · Research Square · doi:10.21203/rs.3.rs-2189033/v1
Levandovska, K. V., Tymochko, N. B., & Naluzhna, T. V. (2023) · Acta Balneologica · doi:10.36740/abal202301104
Catapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00013-3 · Cited by 1
Omari, M., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113665
Гиляревский, С. Р. (2018) · Eurasian heart journal · doi:10.38109/2225-1685-2018-3-62-75
Comparing the effect profile of CETP in individuals of East Asian and European ancestriesPreprint
Dunca, D., Chopade, S., Gordillo‐Marañón, M., Hingorani, A. D., Kuchenbaecker, K. B., Finan, C., & Schmidt, A. F. (2023) · medRxiv · doi:10.1101/2023.05.26.23290616
Paradoxical mortality differential of HDL cholesterol
Mukhopadhyay, J., Mallik, D., & Garg, S. (2023) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v14i5.50292
Sui, Z., Cheng, H., Yang, L., Zhou, M., Wu, K., Shi, R.-P., & Wang, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3362254/v1
Lipoproteína (a) y oligonucleótidos antisentido
Romero, J. A. C., Gomez, K. G. C., Ortigoza, M. P. M., & Saavedra-López, H. F. (2023) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.10.3.808
Clarke, R., & Baigent, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00092-2
Zhao, H., Jiang, W., Song, S., Lyu, L., Chang, C., Zhao, Y., Wu, B., Wang, L., & Girgenti, M. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3229244/v1
Francis, K. (2023) · International Journal of Biochemistry & Physiology · doi:10.23880/ijbp-16000225
Le, N. N., Tran, T., Gill, D., & Padmanabhan, S. (2023) · medRxiv · doi:10.1101/2023.10.18.23297196
Schmidt, A. F., Davidson, M. H., Ditmarsch, M., Kastelein, J. J. P., & Finan, C. (2023) · medRxiv · doi:10.1101/2023.11.03.23298058
Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a)
Guédon, A. F., Ghrenassia, E., Cohen, A. A., & Boccara, F. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.003
PRINCIPAIS EVIDÊNCIAS SOBRE DIAGNÓSTICO E INTERVENÇÕES TERAPÊUTICAS DA SÍNDROME CORONARIANA AGUDA
Nogueira, D. R., Melo, G. C. D. C., Silva, I. D. A. C. E., Moreira, L. E. P., Pedrosa, M. D. S. B., Cardinali, M. D. P., Peron, P. L. V., & Piazzi, R. G. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p41
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.135
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.136
Labordiagnostik von Fettstoffwechselstörungen
März, W., Scharnagl, H., Kleber, M. E., Silbernagel, G., Nauck, M., Müller‐Wieland, D., & von Eckardstein, A. (2024) · Diabetes aktuell · doi:10.1055/a-2302-8505
Coronary atherosclerotic plaque regression strategies
Poznyak, A. V., Yakovlev, A. А., Popov, M. A., Zhuravlev, A. D., Sukhorukov, V. N., & Orekhov, A. N. (2024) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230223
RetractedGurian, A. D. O. V., Teles, A. E. L., Bozi, A., Mantovi, C. K., Moreira, F. G., da Silva, F. M. A., Gonçalves, L. B., Silveira, T. L. D. S., da Silva, T. B., & Lista, P. V. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p121
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Larifla, L., Bassien-Capsa, V., Vélayoudom, F.-L., Chingan-Martino, V., Afassinou, Y. M., Ancédy, Y., Galantine, O., Galantine, V., Nicolas, L., Martino, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011140
Reducing CETP activity prevents memory decline in an Alzheimer’s disease mouse model
Phénix, J., Sarty, I. M., Katz, M. S., Cobá, A. V., Marure-Rojano, A. E., Nie, H., Kerksiek, A., Jerry, I., Berger, C. S., Kiss, R. S., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00482-w · Cited by 3
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.09.001
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752
Lp(a). Lo que sabemos, lo que desconocemos y lo que esperamos
Moyá-Amengual, A., & Serrano-Cumplido, A. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102451
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.101523
Li, X., Xue, H., Yang, S., Li, Y., Dai, C., Mai, J., Li, J. B., Li, Y., & Bao, H. (2025) · Angewandte Chemie · doi:10.1002/ange.202510560
Cholesteryl ester transfer protein activity correlates inversely with apolipoprotein A5 levels
Wen, Y., Li, H., Smith, S. A., Lin, Y., Chen, Y., Bellinger, M. A., Zhen, Y., Beyer, T. P., Siegel, R. W., Qian, Y., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.008
Weekly Journal Scan: obicetrapib and the revival of cholesteryl ester transfer protein inhibition
Vergallo, R., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf467
Choe, Y. M., Choi, H., Keum, M., Lee, B. C., Suh, G., Kim, S. G., Kim, H. S., Hwang, J., Yi, D., & Kim, J. W. (2025) · Nutrients · doi:10.3390/nu17142321
Satapathy, P., Mehta, R., & Sah, R. (2025) · American Journal of Reproductive Immunology · doi:10.1111/aji.70150
Thompson, J., Bobou, M., Roberts, K., Taheri, S., Love, S., & Murray, M. L. (2025) · Trials · doi:10.1186/s13063-025-09227-5
Liao, K. P., Rist, P. M., Giles, J., Santacroce, L. M., Connelly, M. A., Glynn, R. J., Ridker, P. M., Tawakol, A., Bathon, J., & Solomon, D. H. (2024) · Figshare · doi:10.6084/m9.figshare.26094432
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2023) · Figshare · doi:10.6084/m9.figshare.24792259
Additional file 1 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624815
Additional file 5 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624827
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26652357
Additional file 3 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624821
Additional file 4 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624824
Additional file 2 of Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2024) · Figshare · doi:10.6084/m9.figshare.26624818
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26652360
Kim, H. J., Jeong, S., Oh, Y. H., Park, S. J., Cho, Y., & Park, S. M. (2023) · Figshare · doi:10.6084/m9.figshare.22623655
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26652363
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2024) · Figshare · doi:10.6084/m9.figshare.24792442
Kristensen, F. P. B., Christensen, D. H., Mortensen, M. B., Mæng, M., Kahlert, J. A., Sørensen, H. T., & Thomsen, R. W. (2024) · Figshare · doi:10.6084/m9.figshare.26606815
Additional file 1 of ANGPTL3 is a novel HDL component that regulates HDL function
Yang, L., Wang, Y., Xu, Y., Li, K., Yin, R., Zhang, L., Wang, D., Wei, L., Lang, J., Cheng, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26691460
Yamashita, S., & Masuda, D. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.16
cHDL reevaluado: nuevos conocimientos y nuevo potencial en la farmacología cardiovascular
Fernández-Olmo, R., Cordero, A., Albarrán, O. G., Miranda, J. L., & Badimón, L. (2026) · REC CardioClinics · doi:10.1016/j.rccl.2025.12.004
Ahmed, A. E., Ismail, H. E.-D. M. M., Fathy, E., Mahmoud, S. E. D., Ezzat, M. A. W., Lotfy, M., Wadie, M., & Altaher, A. M. (2026) · Heart India · doi:10.4103/heartindia.heartindia_61_25
Probucol: revisiting as a multifaceted therapeutic agent in atherosclerosis
Li, S., Liu, H.-H., Rm, X., & Li, J.-J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704983
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
